CommercialAdministrativeMedium impact
07.07.03n, Photodynamic Therapy (PDT) Using Levulan® Kerastick® or Ameluz® (Aminolevulinic Acid HCl [ALA])
Independence Blue Cross·Dermatology, Oncology·Pharmacy
Effective date
Oct 20, 2025
We identified it
Jun 19, 2026
Summary
Policy 07.07.03n has been updated as a medical coding and informational update effective October 20, 2025. This recent policy change affects photodynamic therapy (PDT) billing using Levulan® Kerastick® or Ameluz® (aminolevulinic acid HCl). The billing team must review the updated guidance to ensure accurate coding and compliance with current requirements.
Action Required
By October 20, 2025: Billing team must review and implement Policy 07.07.03n updates for photodynamic therapy (PDT) procedures using Levulan® Kerastick® or Ameluz®. Access the full policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=10&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-07-07-03n to identify specific coding, medical necessity, and coverage requirements. Update billing system templates and provider encounter forms as needed. Communicate any coding changes to clinical staff and ensure all future PDT claims comply with the revised medical coding guidelines. Failure to implement policy updates may result in claim denials or delays.